Activating mutations in KIT are present in about 80% of GIST [11, 40, 44] and lower expression of miRNA221 and miRNA222 may play a role in further enhancing KIT oncogenic influence on the cell in these cases. This evidence concerns the gene KIT and gastrointestinal stromal tumor.